




cohance
lifesciences

Accelerating Advantage



Who We Are

Cohance is a leading CDMO and API platform based in India offering products and services across all phases of a molecule's lifecycle from development to commercialization. We innovate, co-create and collaborate with Innovators and marquee pharmaceutical and speciality chemical companies to deliver high standard products that enhance quality of people's lives with strong focus on fundamentals such as ESG, quality and compliance.

Cohance Lifesciences Ltd.

ZCL Chemicals Ltd.

Avra Laboratories Pvt. Ltd.

Vision

Co-create a Top 3 CDMO and merchant API platform by serving global marquee pharma and speciality chemical customers as their partner of choice. While striving to achieve a dominant position in the chosen high defensibility segments, we deliver transformational impact to our client, enhance the quality of life of millions of patients and set industry leading best-in-class standards.

Our Values


unity


simplicity


passion


accountability


agility

Business Verticals



CDMO Services

Flexible and custom solutions for challenging development & manufacturing needs



API + and Formulations

Partner of choice for complex molecules



Clinical and Analytical Services

High class clinical solutions for Bio availability & Bio equivalence studies



Cohance at a Glance



Our Journey of firsts and milestones



Completed 7 Successful
Regulatory audits in 2023



Pioneer in the world to
develop synthetic route for
Camptothecin derivatives.



India's largest player in custom
development and manufacturing of
high purity electronic chemicals



Cohance's technology platform:
A gateway for different
payloads for ADC's.



Growing basket of 80+ molecules backed
by robust R&D, regulatory capabilities
and manufacturing infrastructure



Amongst top 3 players globally
in 8 to 10 Molecules



One of the largest backward integrated
pellets exporters from India



OEB 5 containment
capabilities



Developed unique platform technologies
like cross coupling chemistry using different
catalysts at gram scale to multi kilo scale



Over 15 years of experience in development
and manufacturing of complex heterocyclic,
chiral aliphatic, acyclic compounds

Infrastructure- Best-in-class facilities built on world-class standards

Designed to conform to cGMP and approved by international regulatory bodies (US FDA, EU GMP, PMDA, TGA, ANVISA, WHO)

100+

Dryers: RCVD, VTD, FBD, ANFD, TD and Nauta

7

Multi-purpose, multi-product cGMP manufacturing units

API

- 5 API Manufacturing units
- Installed reactor capacity of 1250+ KL with SSR, GLR and Cryogenic reactors, ranging from 50 L to 12,500 L.
- 21 Powder processing areas as per class ISO 8 (Class 100,000).
- Reaction Temperature ranging from -100°C to +220°C
- High vacuum distillation at 1 Torr and high-pressure reactions at 20 Bar in combination of 200°C temperature
- Oncology drugs manufacturing and OEB-5 classification containment capabilities



FDF and PFI

- 2 Dedicated manufacturing units
- FDF: Installed capacity of 1800 million oral solid dosage with two blocks and multiple modules
- PFI: Installed capacity of 830 MT.
- ISO 8, Safety and quality complaint. 7 modules for PFI manufacturing
- Development and manufacture of advanced drug delivery systems with emphasis on sustained release under cGMP conditions.
- Accredited by USFDA, MOH-Russia, Health Canada, PMDA, SFDA, and other global authorities



CRBIO

- Clinical units with 114 beds with 6 beds fully equipped ICU
- Bioanalytical unit with 9 LC/MS-MS
- In-house Pharmacokinetics & Statistics with latest Softwares like WinOnline / SAS
- Facility has been accredited by regulatory authorities such as USFDA, UK-MHRA, NPRA- Malaysia, WHO-Geneva, GCC, DCGI etc.




Our Journey Towards Excellence



Regulatory Approvals




Cohance in numbers



ESG - Shaping Our World

ESG framework made an integral part of operations ISO 14001, ISO 45001 and ISO 9001 accreditations





Research and Development

Our technology and expertise to simplify complex chemistries



4 R&D facilities with a combined 45000 Sq. ft built up area



Highly skilled and diverse team comprising of PhD's, post graduates and chemical engineers



Expertise in handling multi-step complex chemistry, extended coupling reactions including the development of suitable analytical chiral methods



State-of-the art Analytical labs with sophisticated instruments along with stability & photo stability chambers



Capability to handle and develop cytotoxic intermediates / API



Capability for evaluation & development including validation of analytical test methods for Genotoxic and Nitrosamine impurities



Capability to carry out full-scale patent evaluation



Development of non-infringing processes & collaborative programs under confidentiality agreement

R&D Core Competence

Carbonylations using carbon monoxide on multi kilo scale

Palladium Foray into Coupling Reactions for C-C and C-N bond formations

Capability to handle high potency molecules

LaCl₃ / LiCl catalysed Alkyl Grignard reactions

Cryogenic (up to -90°C), organometallic, pyrophoric reagents and reactions

- Suzuki Coupling using Miyaura borylated species
- Negishi Coupling with alkyl zinc bromides
- Stille: Between organohalides & organotin compounds
- Buchwald Hartwig: Between aryl halide & amine or aryl alcohol
- Tsuji-Trost: Between alkene and a nucleophile
- Heck- Matsuda: Between alkenes and alkyl halides
- Chiral separations & Reductive amination

- Expertise in selection of Palladium catalyst & ligands such as:
 - Pd(OAc)₂, Pd₂(dba)₃.DCM, Pd(PPh₃)₄, Pd(PPh₃)₂Cl₂
 - RuPhos, SPhos, X-Phos and xantphos
- Gilman reaction on production scale
- Solid distillation (Upto 0.01 torr)
- Phase Transfer Catalysis
- Copper catalyzed Ullmann Reaction

Active Pharma Ingredients - Commercial

Product	USDMF	CEP	EDMF	C-DMF	CA-DIFA	KDMF	RUSSIA	OTHERS	Therapeutic Use
Apixaban	√		*	*	√	√	*	* TDMF, JDMF	Anticoagulant
Aripiprazole	√	√	*	*	*	√		* JDMF	Antipsychotic, Antidepressant
Articaine Hcl		√	*			√	*		Dental Anesthetic
Atomoxetine Hcl	√	√	*	√				TDMF, Canada	ADHD
Baclofen	√	√	*	*	*	√	*	* JDMF	Skeletal Muscle Relaxant
Bempedoic Acid	*								Antilipemic agent
Benserazide		√							Antifibrinolytic
Betahistine DiHcl		√	*	√	√				AntiVertigo
Cannabidiol	*								Anticonvulsant, Antipsychotic, Muscle relaxant
Dapagliflozin Propanediol Monohydrate	√			*	√	√			Antidiabetic
Dexmethylphenidate Hcl								Tech Pack	ADHD
Diflunisal	√		*	√					NSAID
Dipyridamole	√	√	*	√	*	√	√	TGA	Antiplatelet
Doxazosin Mesylate		√	*	√			√		Antihypertensive
Drotaverine Hcl			√	*			√		Antispasmodic
Entacapone	√	√	*	√	√	√	*	TDMF, *JDMF	Antiparkinson
Flurbiprofen		√	*			√		* JDMF	NSAID
Fluvoxamine Maleate	√	√	*	*	*	*	*	TDMF	Antidepressant
Hydralazine Hcl	√			*	*	*		* JDMF	Antihypertensive
Lamotrigine	√	√	*	√	√	√	*	* JDMF	Antiepileptic
Levodropropizine		√							Anti-anginal, Antihypertensive, Cardiotonic
Levomepromazine Maleate		√	*						Antipsychotic
Lurasidone Hcl	√								Antipsychotic
Lisdexamfetamine dimesylate					√				ADHD
Maraviroc	√							TDMF	Antiretroviral
Mebeverine		√	*	*	*		√	TGA, TDMF	Antispasmodic
Methylphenidate Hcl		√	*		√				ADHD
Mexiletine	*	*							Antiarrhythmics
Mexiletine Hcl	√								Antiarrhythmia

** ZCL Chemicals | ## RA Chem √ filed * Under filing



Active Pharma Ingredients - Commercial

Product	USDMF	CEP	EDMF	C-DMF	CA-DIFA	KDMF	RUSSIA	OTHERS	Therapeutic Use
Midazolam	√	√	*		√	√		TDMF	Anesthetic
Midazolam Hcl			√		√				Anesthetic
Midazolam Maleate									Anesthetic
Mirabegron	√					√			Treatment of overactive bladder
Oxolamine Citrate								TDMF	Cough suppressant / Anti Inflammatory
Oxolamine Phosphate									Cough suppressant / Anti Inflammatory
Pirfenidone	√	√	*	√	*	√			AntiInflammatory, Antirheumatic
Posaconazole	√		*	*	*	*	*	* JDMF	Antifungal
Quetiapine Fumarate	√	√	*	*	√	√		TGA	Antipsychotic
Ractopamine Hcl	√							Canada	β - Adrenergic Agonist (V)
Rivaroxaban	√	√	*	*	√	√	*	* JDMF	Anticoagulant
Tamsulosin Hcl	√	√	*	√			√	TDMF	Benign Prostatic Hyperplasia
Tapentadol Phosphate			√						Anesthetic
Ticagrelor	√	√	*	*		√		* JDMF	Platelet aggregation inhibitor
Trimetazidine dihydrochloride		*							Antianginal
Venlafaxine Hcl	√	√	*	√	*	*	*	* JDMF	Antidepressant
Zilpaterol									β2 adrenergic agonist
Zonisamide **	√		√			√		TDMF, JDMF	Anticonvulsant
Zonisamide ###	√			√					Anticonvulsant

Active Pharma Ingredients - Under Development / Evaluation

Product	Therapeutic Use	Status
Buspirone	Anti anxiety	Under Evaluation
Dabigatran Etexilate Mesylate	Antihypertensive	Under Validation
Desvenlafaxine	Antithrombotic	Under Evaluation
Lercanidipine	Antidepressant, Anxiolytic	Under Evaluation
Loxoprofen	Antitussive, Cough suppressant	Under Evaluation
Moxonidine	Antihypertensive	Under Evaluation
Oxymetazoline	Decongestant, Vasoconstrictor	Under Validation
Remimazolam Besylate	Sedative, General Anesthetic	Under Validation
Trazodone	Antidepressant	Under Evaluation
Trimebutine Maleate	Antimuscarinic Agent	Under Evaluation

** ZCL Chemicals | ## RA Chem √ filed * Under filing

Oncology Portfolio

Antibody Drug Conjugates (ADC's) - Payloads

Product	Use	Current Status	CAS No.
7-Ethyl-10-hydroxycamptothecin (SN-38)	Payload Intermediate	Commercial	86639-52-3
(S)-8-Ethyl-8-hydroxy-2,3,5,8-tetrahydro-6-oxa-3a-aza-cyclopenta [b]naphthalene-1,4,7-trione (S-trione)	Payload Intermediate	Commercial	110351-94-5
MMAE (Auristatin)	ADC payloads	Sample Available	474645-27-7
Exatecan Mesylate Di-hydrate	ADC payloads	Under Development	197720-53-9
MMAF (Auristatin)	ADC payloads	Under Development	745017-94-1
DM1 (Maytansinoid)	ADC payloads	Under Development	1018448-65-1
DM4 (Maytansinoid)	ADC payloads	Under Development	1453084-37-1
SN-22	ADC payloads	Technology Available. Can be taken-up on request	17403-07-5
Silatecan	ADC payloads	Technology Available. Can be taken-up on request	220913-32-6
Rubitecan	ADC payloads	Technology Available. Can be taken-up on request	91421-42-0
Belotecan	ADC payloads	Technology Available. Can be taken-up on request	213819-48-8

Active Pharma Ingredients

Product	Plant Validation	Current Status	CAS No.
Irinotecan Hydrochloride	Completed	Commercial	136572-09-3
Lenalidomide (Form-I, Form-B, Form-A*)		Commercial	847871-99-2 (Form B)
Methotrexate	Q1 2024	Under Development	59-05-2
Topotecan Hydrochloride		Under Development	119413-54-6

Intermediates

Product	Use	Current Status	CAS No.
3 -Amino-Piperidine-2,6-Dione HCl	Lenalidomide	Commercial	24666-56-6
3-Nitro-2- Bromomethyl Methyl Benzoate	Lenalidomide	Commercial	98475-07-1
2'-Amino-5'-hydroxypropiophenone (AHP)	Irinotecan	Commercial	35364-15-9
N-(4-(methylamino)benzoyl)-l-glutamic acid diethyl ester	Methotrexate	Commercial	2378-95-2



Intermediates List

Product	CAS Number	End Use
Phenyl-(2-pyridyl acetamide)	7251-52-7	Methylphenidate
Phenyl-2-(2'-piperidyl) acetamide	19395-39-2	Methylphenidate
threo-phenyl-2-piperidyl acetamide*	50288-62-5	Methylphenidate
dl-threo-Ritalinic acid*	54631-24-2	Methylphenidate
d-threo-Ritalinic acid HCl*	741705-70-4	Dex Methylphenidate
Tert-butyl N-[(2S)-6-[(2-methylpropan-2-yl)oxycarbonylamino]-1-oxo-1-[[[(2S)-1-phenylpropan-2-yl]amino]hexan-2-yl]carbamate (Lisdexamfetamine Intermediate (LDX-I)	819871-13-1	Lisdexamfetamine dimesylate
2-aminomethyl-7-chloro-2,3-dihydro-5-(2-fluorophenyl)-1h-1,4-benzodiazepine dimaleate	59469-29-3	Midazolam
2-[(2S)-oxiran-2-ylmethyl]-1H-isoindole-1,3(2H)-dione	161596-47-0	Rivaroxaban
5-chlorothiophene-2-carboxylic acid	24065-33-6	Rivaroxaban
(2S, 3R)-1-(Dimethylamino)-3-(3-methoxyphenyl)-2-methyl-3-pentanol	809282-20-0	Tapentadol HCL/ Tapentadol Phosphate
3-Methoxy propiophenone	37951-49-8	Tapentadol HCL/ Tapentadol Phosphate
3-Hydroxy propiophenone	13103-80-5	Tapentadol Phosphate
2-(2,3-Dichlorophenyl)-2-(guanidinylimino)acetonitrile (Schiff Base)	84689-20-3	Lamotrigine
Methyl Olivetolate	58016-28-7	Cannabidiol
Olivetol	500-66-3	Cannabidiol
Menthadienol (MTH)	22972-51-6	Cannabidiol and Dronabinol family
4-Amino-2-chloro-6,7-dimethoxyquinazoline	23680-84-4	Doxazosin Mesylate
Methyl 3-((3S)-7-bromo-2-((2-hydroxypropyl)amino)-5-(pyridin-2-yl)-3H-benzo[e][1,4]diazepin-3-yl)propanoate (REM-II)	308243-54-1	Remimazolam Besylate
(S)-2-((S)-4-methyl-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)pentanamido)-3-phenylpropanoic acid	868540-16-3	Carfilzomib
(S)-2-amino-4-methyl-1-((R)-2-methyloxiran-2-yl)pentan-1-one trifluoroacetic acid salt	247068-85-5	Carfilzomib
(5-Bromo-2-chlorophenyl)(4-ethoxyphenyl)methanone	461432-22-4	Dapagliflozin and Ertugliflozin
5-Bromo-2-chloro-4'-ethoxydiphenylmethane	461432-23-5	Dapagliflozin and Ertugliflozin
(S)-8-Ethyl-8-hydroxy-2,3,5,8-tetrahydro-6-oxa-3a-aza-cyclopenta [b]naphthalene-1,4,7-trione	110351-94-5	Irinotecan
2'-Amino-5'-hydroxypropiophenone	35364-15-9	Irinotecan
7-Ethyl-10-hydroxycamptothecin (SN-38)	86639-52-3	Irinotecan
10-Hydroxycamptothecin	19685-09-07	Topotecan
4-Fluoro-2-methoxy-5-nitroaniline	1075705-01-9	Osimertinib
N-(4-Fluoro-2-methoxy-5-nitrophenyl)-4-(1-methyl-1H-indol-3-yl)-2-pyrimidinamine	1421372-94-2	Osimertinib
2-Amino-5-bromobenzaldehyde	29124-57-0	
2-phenylpyridine	1008-89-5	
3-Bromopyridazine Hydrobromide	----	
3-Hydroxyazetidine hydrochloride	18621-18-6	
6-Hydroxy-1,2,3,4-tetrahydroisoquinoline	14446-24-3	
Trimethylsulfoxonium chloride	5034-06-0	
Tri-tert-butylphosphoniumtetrafluoroborate	131274-22-1	

v filed * Under filing

Pre Formulation Intermediates (Pellets)

Product name	DMF/ Techpack	Bio equivalence established	Type of BE study	RLD/ Market	Stability	Brazil	Turkey	Mexico	MENA	APAC
Duloxetine DR Pellets 17% (HPMC Phthalate)	DMF	No		Cymbalta	6M	DMF#		DMF#	Yes	
Duloxetine HCl DR Pellets 20% (HPMC Acetyl succinate)	DMF	Yes	Fast & Fed	Cymbalta/ EU	36M		Yes	Yes		
Duloxetine HCl DR Pellets 20% (HPMC Phthalate)	DMF	Yes	Fast & Fed	Cymbalta/ EU	36M	Yes	Yes			
Fenofibrate SR Pellets 75%	DMF	No			36M	Yes			Yes	
Fenofibric acid DR Pellets 29%	DMF	No			6M		Yes			
Itraconazole IR Pellets 21.74%	DMF	Yes	Fast & Fed	Sporanox/ US	24M			Yes		Yes
Itraconazole IR Pellets 22%	DMF	No			36M	Yes		Yes	Yes	
Lansoprazole Pellets 8.5%	DMF	No *		*Customer established BE in TR	36M	Yes	Yes		Yes	Yes
Mebeverine HCl IR Pellets 40%	DMF	No			36M				Yes	
Mebeverine HCl IR Pellets 46%	DMF									
Mebeverine HCl SR Pellets 72%	DMF	No			24M					
Mebeverine HCl SR Pellets 80%	DMF	Yes	Fast & Fed MDD/SS	Colofac & MR/EU	36M			Yes	Yes	
Methylphenidate HCl ER Pellets 11%	DMF	Yes	Fast & Fed	Ritalin LA/BR	6M (Mar/24)	DMF#				
Metoprolol SR Pellets 66%	DMF	No *		*Customer established BE in TR	36M		Yes			
Omeprazole DR Pellets 8.5% (LD-30)	DMF	No			36M			Yes	Yes	Yes
Omeprazole Pellets 8.5% (Phthalate)	DMF	No			36M	Yes	Yes	Yes		
Orlistat IR Pellets 50% (Extrudes)	DMF	No		Xenical/EU	36M	Yes		Yes		
Posaconazole Granules 16.39%	DMF	Yes	Fast & Fed US	NOXAFIL NA	24M					

Under compilation



Pre Formulation Intermediates (Pellets)

Product name	DMF/ Techpack	Bio equivalence established	Type of BE study	RLD/ Market	Stability	Brazil	Turkey	Mexico	MENA	APAC
Tamsulosin ER Pellets 0.12%	NA	Yes	Fast & Fed US, CAN	Flomax/ NA	6M (May/24)			Yes		
Tamsulosin HCl ER Pellets 0.2%	DMF	No			36M	Yes	Yes	Yes	Yes	Yes
Venlafaxine HCl ER Pellets 33% (Brazil)	DMF	No			36M	Yes				
Venlafaxine HCl ER Pellets 33% (Regular composition)	DMF	No	Fast & Fed	Effexor/ TR	48M		Yes	Yes		
Venlafaxine HCl ER Pellets 33% (Turkey)	DMF	Yes	Fast & Fed & MDD/SS	Effexor/ EU	6M*		Yes			

Pre Formulation Intermediates - Under Development

Product name	DMF/Techpack	Bio equivalence established	Type of BE study	RLD/Market	Stability
Galantamine HBR ER Pellets, 8%	Tech pack	Yes	Fast/Fed	Reminyl ER/EU	6M
Dabigatran etexilate SR pellets 36.8% w/w	Tech pack	Yes	Fast	PRADAXA/US	6 M
Dabigatran etexilate SR pellets 35% w/w	Tech pack	No		PRADAXA/US	6 M
Dexlansoprazole DR pellets 22.5% w/w	Tech pack	Yes	Fast/Fed	DEXILANT/US	6 M (May/24)
Dexlansoprazole DR pellets 20% w/w	Tech pack	No		DEXILANT/US	6 M (Jun/24)
Dipyridamole SR pellets 41.76% w/w	Tech pack	Yes	Fast & Fed	AGGRENOX/US	6 M
Esomeprazole DR pellets 22.5% w/w	Tech pack	Yes	Fast	NEXIUM/EU	12 M
Memantine SR pellets 14 % w/w	Tech pack	Yes	Fast & Fed	NAMZARAC/US	6 M
Trimetazidine Pellets 53 %	Tech pack	No		Vastarel MR /BR/TR	
Tamsulosin HCl SR Pellets, 0.16%	DMF	No			6M (Jun/24)
Mebeverine HCl SR Pellets, 46%	DMF	No			6M(Jul/24)

Finished Dosage Formulation (CDMO/ CMO partner)

Product	Strength	ANDA	EU Dossier	ANDS	Countries for which Dossier are available
Baclofen Tablets	5mg, 10mg, 20mg	Approved	Not filed	Not filed	Globally
Cinacalcet Tablets	30mg, 60mg, 90mg	Approved	Approved	Not filed	Except EU
Doxazosin Tablets	1mg, 2mg, 4mg, 8mg	Approved	Not filed	Approved	Except USA, CA, EU, APAC
Entecavir Tablets film coated	0.5mg, 1mg	Approved	Approved	Approved	Except USA, EU, CA, SEA, MENA
Eplerenone Tablets	25mg, 50mg	Approved	Not filed	Not filed	
Esclicarbazepine Tablets	800 mg	Not filed	Approved	Not filed	Except EU
Itraconazole Capsules	100 mg	Approved	Not filed	Approved	Aus, CA, ROW
Mebeverine HCl Tablets	135 mg	Not filed	Approved	Approved in Aus	Except UK, Aus, EU
Mebeverine SR Capsules	200 mg	Not filed	Approved	Not filed	Except EU
Meclizine Tablets	12.5mg, 25mg	Not filed	Not filed	Not filed	Globally except Aus & NZ
Methocarbamol Tablets	500 mg	Approved	Not filed	Not filed	Except USA
Methocarbamol Tablets film coated	750 mg	Approved	Approved	Not filed	Except USA, Germany
Posaconazole DR Tablets	100 mg	Approved	Not filed	Not filed	Except USA, MENA
Propiomazine Tablets	25 mg	Not filed	Approved	Not filed	Except Scandivian countries
Tamsulosin HCl Capsules	0.4 mg	Approved	Not filed	Approved	Except CA



Finished Dosage Formulation - Under Development

Product	Strength	Status
Aspirin+Dipyridamole	25/200mg	Proof of concept developed
Diflunisal Tablets	500 mg	Proof of concept developed
Dipyridamole Capsules	200 mg	Proof of concept developed
Solifenacin & Tamsulosin PR Tablets	6mg/0.4mg	Proof of concept developed
Verapamil HCl SR Capsules	120mg, 180mg, 240mg, 360mg	To be initiated
Dabigatran Capsules	75 mg, 110 mg, 150 mg	Proof of concept developed
Dexlansoprazole DR Capsules	30 mg and 60 mg	Proof of concept developed
Hydralazine HCl Tablets	10 mg, 25 mg, 50 mg and 100 mg	Proof of concept developed
Methylphenidate HCl ER Capsules	10 mg, 20 mg, 30 mg and 40 mg	Proof of concept developed
Aripiprazole Oral Dispersible Tablets	2 mg, 5 mg, 10 mg, 15 mg, 20 mg, 30 mg	To be initiated
Hydralazine Hydrochloride + Isosorbide Dinitrate	20mg/37.5mg	Proof of concept under development
Lamotrigine Chewable Tablets	2mg, 5mg, 25mg	Proof of concept developed
Levodopa + Benserazide Dispersible Tablets	50mg +12.5mg, 100mg +25mg	To be initiated
Levodopa + Benserazide IR Capsules	50mg +12.5mg, 100mg + 25mg, 200mg + 50mg	Proof of concept under development
Levodopa + Benserazide IR Tablets	50mg +12.5mg, 100mg + 25mg, 200mg + 50mg	Proof of concept under development
Levodopa + Benserazide PR Capsules	100mg +25mg, 200mg + 50mg	Proof of concept under development
Nafronyl MR Tabs	100 mg	To be initiated
Trimetazidine MR Tablets	35 mg	To be initiated



cohance

lifesciences



Registered Office

215 Atrium, C Wing, 8th Floor, 819-821,
Andheri Kurla Road, Andheri (East),
Mumbai – 400093, Maharashtra, India

Tel: +91 22 61539999

Fax: +91 22 61539997

Corporate Office

Galaxy, Floor- 02, Plot No.1, Knowledge City,
Raidurg Panmaktha, Ranga Reddy District,
Hyderabad – 500032 Telangana, India

Tel: +91 40 44758595

Fax: +91 40 44758596

API Manufacturing Sites

API Unit-I

R.S. No. 50/1, Mukteswarapuram
Village, Jaggaiahpet Mandal,
NTR District – 521457,
Andhra Pradesh, India.

API Unit-II

Plot No. 27C, Denotified Area,
APSEZ, Gurajapalem Village,
Rambilli Mandal, Atchutapuram,
Anakapalli District -531011,
Andhra Pradesh, India.

API Unit-III

ZCL Chemicals Ltd
Plot No: 3102/B, GIDC Estate
Ankleshwar, Bharuch Dist,
Gujarat, India - 393002

API Unit-IV

AVRA Laboratories Pvt Ltd
Plot No.A-21, Road No. 10,
IDA Nacharam,
Uppal -500076
Telangana, India.

API Unit-V

Avra Laboratories Pvt., Ltd.,
Plot No.48, Road No.7,
J.N.Pharmacy, Parawada,
Anakapalli District - 531021
Andhra Pradesh, India.

API R&D-I

Plot No.8&9B/40, Survey Nos.29,39,
40&41, Mirra Industrial Estate,
IDA Phase I, Patancheru,
Sangareddy District - 502319,
Telangana, India.

FDF/ PFI/ CR Bio Sites

FDF Unit-I

Plot No. A-19/C, A-23A, A-23B,
Road No. 18, IDA Nacharam,
Uppal Mandal, Medchal – Malkajgiri
District – 500076, Telangana, India.

FDF Unit-II

Plot No. P1/B, Survey No: 423(P) & 424(P),
Green Industrial Park, TSIIC, Polepally Village,
Jadcherla Mandal, Mahabubnagar
District - 509301, Telangana, India.

FDF R&D

Plot No.10/8, A-Block, 4th Floor,
CDC Towers, Road No.05, IDA,
Nacharam Village, Uppal Mandal,
Medchal – Malkajgiri District - 500076,
Telangana, India.

Clinical Research and Biosciences

Plot No: 26 & 27, Techno Industrial
Estate, Balanagar, Hyderabad – 500037
Telangana, India



Scan to download
the e-Brochure